The new Global Multiple Sclerosis Severity Score (MSSS) correlates with axonal but not glial biomarkers

This study investigated whether the new Global Multiple Sclerosis Severity Scale (MSSS) correlated with cerebrospinal fluid biomarkers for axonal and glial pathology. The MSSS correlated with the phosphorylated neurofilament heavy chain (NfH-SMI35, R=0.44, P=0.016). The degree of neurofilament phosp...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Multiple sclerosis 2006-06, Vol.12 (3), p.325-328
Hauptverfasser:	Petzold, A, Eikelenboom, M J, Keir, G, Polman, C H, Uitdehaag, B MJ, Thompson, E J, Giovannoni, G
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Axons - metabolism Axons - pathology Biological and medical sciences Biomarkers - cerebrospinal fluid Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases Diagnostic Techniques, Neurological - standards Female Humans Immunomodulators Linear Models Male Medical sciences Middle Aged Multiple Sclerosis - cerebrospinal fluid Multiple Sclerosis - pathology Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis Nerve Degeneration - cerebrospinal fluid Nerve Degeneration - pathology Neurofilament Proteins - metabolism Neuroglia - pathology Neurology Pharmacology. Drug treatments Phosphorylation Severity of Illness Index
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	This study investigated whether the new Global Multiple Sclerosis Severity Scale (MSSS) correlated with cerebrospinal fluid biomarkers for axonal and glial pathology. The MSSS correlated with the phosphorylated neurofilament heavy chain (NfH-SMI35, R=0.44, P=0.016). The degree of neurofilament phosphorylation (ratio NfH-SMI34 to NfH-SMI35) was 8-fold higher in severely (median MSSS 6.5) versus mildly (MSSS 3.2) disabled patients (7.3 versus 0.9, P=0.03). The MSSS may provide a statistically powerful tool for comparing overall disease severity and be useful for validating the biomarker concept in MS.
ISSN:	1352-4585 1477-0970
DOI:	10.1191/135248505ms1277oa